JPWO2024039672A5 - - Google Patents

Info

Publication number
JPWO2024039672A5
JPWO2024039672A5 JP2025508673A JP2025508673A JPWO2024039672A5 JP WO2024039672 A5 JPWO2024039672 A5 JP WO2024039672A5 JP 2025508673 A JP2025508673 A JP 2025508673A JP 2025508673 A JP2025508673 A JP 2025508673A JP WO2024039672 A5 JPWO2024039672 A5 JP WO2024039672A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025508673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025528835A (ja
JP2025528835A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/030268 external-priority patent/WO2024039672A2/en
Publication of JP2025528835A publication Critical patent/JP2025528835A/ja
Publication of JPWO2024039672A5 publication Critical patent/JPWO2024039672A5/ja
Publication of JP2025528835A5 publication Critical patent/JP2025528835A5/ja
Pending legal-status Critical Current

Links

JP2025508673A 2022-08-15 2023-08-15 Mslnに対する抗体及びその使用方法 Pending JP2025528835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263398082P 2022-08-15 2022-08-15
US63/398,082 2022-08-15
PCT/US2023/030268 WO2024039672A2 (en) 2022-08-15 2023-08-15 Antibodies against msln and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2025528835A JP2025528835A (ja) 2025-09-02
JPWO2024039672A5 true JPWO2024039672A5 (https=) 2025-11-04
JP2025528835A5 JP2025528835A5 (https=) 2025-11-04

Family

ID=87974270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025508673A Pending JP2025528835A (ja) 2022-08-15 2023-08-15 Mslnに対する抗体及びその使用方法

Country Status (7)

Country Link
EP (1) EP4573118A2 (https=)
JP (1) JP2025528835A (https=)
KR (1) KR20250108093A (https=)
CN (1) CN119855829A (https=)
AU (1) AU2023324669A1 (https=)
CA (1) CA3263672A1 (https=)
WO (1) WO2024039672A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025255291A1 (en) * 2024-06-07 2025-12-11 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting mesothelin and use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20140004121A1 (en) * 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
KR20230041739A (ko) 2016-03-08 2023-03-24 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
JP7269167B2 (ja) 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
JP7231549B2 (ja) 2017-02-06 2023-03-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
WO2019051122A2 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
US20210070860A1 (en) 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules

Similar Documents

Publication Publication Date Title
JP7551693B2 (ja) NKp46結合タンパク質の可変領域
JP7550591B2 (ja) 多重特異的NKp46結合タンパク質
US20220135676A1 (en) Multispecific antigen binding proteins
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
RU2767357C2 (ru) Биспецифические антитела-ингибиторы контрольных точек
US11202828B2 (en) Therapeutic SIRP-α antibodies
TW202342544A (zh) 抗cd38抗體及其使用方法
CA3198590A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
TW201803899A (zh) 三特異性和/或三價結合蛋白
CN116745317B (zh) 抗tigit抗体及其用途
CN107428830A (zh) 单体fc结构域
CA3139508A1 (en) Materials and methods for modulating t cell mediated immunity
AU2021214622B2 (en) Means and method for modulating immune cell engaging effects.
CA3207791A1 (en) Anti-cd112r antibody and use thereof
TW202241967A (zh) 基於茚地那韋的化學二聚化t細胞銜接器組成物
AU2021224787A1 (en) CD137 binding molecules and uses thereof
KR20240036142A (ko) 3특이성 및/또는 3가 결합 단백질
US20250011422A1 (en) Siglec-6 antibodies, derivative compounds and related uses
JPWO2024039672A5 (https=)
EP4574844A1 (en) Multispecific antibodies having specificity for cd47 and pdl1
WO2025149029A1 (zh) 抗cd28抗体及其用途
HK40100726A (zh) 抗tigit抗体及其用途
RU2025120810A (ru) Антитела против pdl1, полиспецифические антитела и способы их применения